27.34
-0.985(-3.48%)
Currency In USD
| Previous Close | 28.32 |
| Open | 28 |
| Day High | 28.46 |
| Day Low | 27.28 |
| 52-Week High | 46 |
| 52-Week Low | 22.24 |
| Volume | 260,347 |
| Average Volume | 1.56M |
| Market Cap | 1.59B |
| PE | -3.9 |
| EPS | -7.01 |
| Moving Average 50 Days | 31.3 |
| Moving Average 200 Days | 34.09 |
| Change | -0.99 |
If you invested $1000 in Agios Pharmaceuticals, Inc. (AGIO) 10 years ago, it would be worth $607.04 as of January 13, 2026 at a share price of $27.335. Whereas If you bought $1000 worth of Agios Pharmaceuticals, Inc. (AGIO) shares 5 years ago, it would be worth $587.85 as of January 13, 2026 at a share price of $27.335.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S. regulatory submission to fo
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that its manage
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
GlobeNewswire Inc.
Dec 24, 2025 12:45 AM GMT
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) remains the U.S